Pieris Pharmaceuticals Inc
0.0 %
7744.39 %
Yet to be announced
Company Overview
Pieris Pharmaceuticals Inc is a clinical-stage biotechnology company that develops novel biotherapeutics through its proprietary Anticalin technology platform. The company focuses on developing treatments for respiratory diseases, cancer, and other therapeutic areas. Their lead respiratory program includes PRS-060/AZD1402, being developed in collaboration with AstraZeneca for asthma treatment.
Revenue Sources
The company is currently in a pre-revenue research and development phase, primarily focused on developing novel therapeutics. Their limited revenue comes from collaboration agreements and licensing fees, which are halal sources of income.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2023 | $1.3m | $5.8m | - | - | 0.00% | 0.00% |
Based on the financial data provided for the last four quarters, the company reports zero interest income and zero interest expense. Additionally, the company is still in its pre-revenue R&D phase, making the interest ratio checks not applicable at this stage of development.
Operational Ethics
After reviewing available company documentation, SEC filings, and public information, there is no evidence of current material associations with entities involved in human rights violations, including the state of Israel or the Chinese Communist Party.
Login to join the discussion